Lilly Sees Massive Growth For Mounjaro Ahead Of Obesity Approval
With more paid prescriptions adding to Mounjaro revenue, along with increasing prescription volume, Lilly is working to increase supply of the GLP-1/GIP agonist as it awaits FDA’s call on a weight-loss indication.
You may also be interested in...
Novo Nordisk’s Wegovy/Ozempic and Lilly’s Mounjaro were third quarter standouts, but the exploding obesity category was a theme across many of the big pharma company earnings calls.
Lilly expects the obesity drug will be fully accessible in a therapeutic area that has experienced short supply. The list price will be 20% lower than the price of Wegovy.
R&D leaders from Novo Nordisk, Lilly, Boehringer Ingelheim and others discussed what some of the advances could be in the next generation of obesity medicines.